Tuesday, October 27, 2026
Two papers, a psychopharmacology pearl, a psychotherapy pearl and the news.
AI-generated content. This briefing was written by Claude Opus 5.5 and may contain errors. Please verify against the primary source before acting clinically.
| The Paper |
| New research from the psychiatric journals |
Reducing suicidal ideation through protective media content in India: randomised controlled trial
Armstrong G, Mohanraj R, Kumar S, Haregu T, Spittal MJ, Niederkrotenthaler T, Pirkis J, Nisha B, Selvan D, Vijayakumar L. British Journal of Psychiatry. September 2026.
Responsible suicide reporting is promoted worldwide, but almost all experimental evidence comes from high-income countries. This three-arm trial in Chennai randomized 375 adults aged 18 to 29 to read three 600-word Tamil-language newspaper articles: educative suicide-prevention content, the same articles plus brief stories of young adults who had coped with suicidal ideation, or control articles about diabetes.
The educative arm improved survival-and-coping beliefs (Reasons for Living subscale) at post-test (SMD 0.15) and at 14 days (SMD 0.17), with larger effects in more vulnerable participants (SMD 0.25 and 0.32). Surprisingly, the coping-story arm showed no immediate benefit and only a marginal effect at follow-up (SMD 0.16, p = 0.053). Effects were small and measured on a beliefs scale rather than behaviour.
|
In practice
Small individual effects matter at population scale, and the benefit was largest in the most vulnerable readers - the people a protective message is meant for. It also tempers the assumption that recovery narratives are automatically the most protective ingredient; plain, educative content about help and warning signs did the work here. |
Full text doi:10.1192/bjp.2026.10799
| The Therapy Evidence |
| Research on what actually works in the room |
Patients' General Versus Personal Expectations About Psychotherapy Change Processes
Asor T, Glushka L, Constantino MJ, Elberg D, Weiser MB, Tzur Bitan D. American Journal of Psychotherapy. September 2026.
Expectations predict psychotherapy outcome, but this study separates two kinds: what people believe therapy does in general, and what they expect it will do for them. 270 people currently in therapy completed the Expectations of Active Processes in Psychotherapy Scale twice - once about therapy in general, once about their own treatment.
For every change process, personal expectations were lower than general ones. The biggest gap was for gaining tools for cognitive control (t = 8.17); the smallest was for exploring unexpressed content (t = 4.02). The gap widened in people with more prior therapy and in those with higher distress, both significant moderators. It is a cross-sectional self-report study without an outcome measure, so it describes expectations rather than proving they change results.
|
In practice
A patient can believe therapy works and still privately doubt it will work for them - and the sickest and most-treated patients doubt it most. Ask about personal expectations specifically in the first sessions, rather than assuming general optimism about therapy transfers to the patient in front of you. |
Full text doi:10.1176/appi.psychotherapy.20250079
| Past the Boards |
| One advanced clinical point, usually pharmacology |
Valproate doubles lamotrigine on the way in, and halves it on the way out
Valproate inhibits lamotrigine's glucuronidation, roughly doubling its half-life and levels. That is why the label halves the bipolar titration on valproate - 25 mg every other day for two weeks, 25 mg daily for two weeks, target about 100 mg/day - and why this combination carries the highest rash risk.
The overlooked direction is removal. A patient stable on lamotrigine 100 mg with valproate who has valproate stopped (pregnancy planning, weight gain, PCOS) loses half the exposure; the label raises lamotrigine to 150 mg for a week, then 200 mg. Missing this produces a quiet relapse attributed to the illness. The reverse also holds: adding valproate to established lamotrigine without cutting the dose by about half recreates the high-rash-risk exposure in someone who has been safe for months. Lamotrigine slightly lowers valproate levels in turn, so recheck the valproate level after starting the combination.
| In the Room |
| A psychotherapy technique, shown in a vignette |
In psychic equivalence, don't argue with the feeling - slow down until it can be a feeling again
In psychic equivalence the inner world is experienced as outer reality: 'I feel rejected' becomes 'you are rejecting me', with no space to consider it as a state of mind. MBT predicts that challenging the content - 'I am not rejecting you' - fails, because the patient is not making a claim that evidence can test. The challenge heightens arousal and the patient feels misunderstood. The technical move is to validate the experience without endorsing the conclusion, lower arousal, and get curious about the moment it began. Once the patient can say 'it felt like' instead of 'it is', mentalizing is back online and alternative perspectives become possible. Interpreting before that point is talking to someone who cannot yet hear it.
|
Vignette
A 26-year-old with borderline personality disorder sees the resident glance at the clock and says, 'You're counting the minutes until I'm gone. You don't want me here.' The resident's impulse is to explain the next appointment. Instead: 'It felt to you like I wanted you gone - that must have hit hard. Can we slow down? What did you notice just before?' She describes the glance, then a wave of shame. The resident adds: 'I did look at the clock. I'm sorry it landed that way. What do you make of what might have been going on for me?' After a pause she says, 'Maybe you were just checking the time.' The shift from certainty to 'maybe' is the outcome of that moment. |
| Elsewhere |
| Developments worth knowing about |
| • | California's AB 1979, signed by Governor Newsom in late September 2026 and effective January 1, 2027, requires a licensed clinician's independent judgment whenever AI informs care. He vetoed SB 903, which would have barred marketing chatbots as therapy, as overbroad - so AI 'therapy' apps remain largely unregulated. Ask patients which ones they use. (source) |
| • | The DEA's fourth extension of telemedicine flexibilities, which allows Schedule II-V prescribing (stimulants, benzodiazepines) without an in-person visit, expires December 31, 2026; as of mid-October no further extension or final rule had been published. Plan in-person evaluations for telehealth-only patients on controlled medications. (source) |
| *** |
| That's the five. Go see your first patient. |